These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 34972658)

  • 1. Self-Reported Severity, Characteristics, and Functional Limitations of Chemotherapy-Induced Peripheral Neuropathy.
    Knoerl R; Mazzola E; Hong F; Salehi E; McCleary N; Ligibel J; Reyes K; Berry DL
    Pain Manag Nurs; 2022 Aug; 23(4):532-540. PubMed ID: 34972658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling.
    Kolb NA; Smith AG; Singleton JR; Beck SL; Stoddard GJ; Brown S; Mooney K
    JAMA Neurol; 2016 Jul; 73(7):860-6. PubMed ID: 27183099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement properties of brief neuropathy screening items in cancer patients receiving taxanes, platinums, or proteasome inhibitors.
    Knoerl R; Mazzola E; Mitchell SA; Hong F; Salehi E; McCleary N; Ligibel JA; Reyes K; Berry DL
    J Patient Rep Outcomes; 2021 Sep; 5(1):101. PubMed ID: 34568984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Painful and non-painful chemotherapy-induced peripheral neuropathy and quality of life in colorectal cancer survivors: results from the population-based PROFILES registry.
    Bonhof CS; Trompetter HR; Vreugdenhil G; van de Poll-Franse LV; Mols F
    Support Care Cancer; 2020 Dec; 28(12):5933-5941. PubMed ID: 32281032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring clinical markers of Axon degeneration processes in Chemotherapy-induced peripheral neuropathy among young adults receiving vincristine or paclitaxel.
    Knoerl R; Mazzola E; Pazyra-Murphy M; Ryback B; Frazier AL; Freeman RL; Hammer M; LaCasce A; Ligibel J; Luskin MR; Berry DL; Segal RA
    BMC Neurol; 2024 Sep; 24(1):366. PubMed ID: 39342135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the impact of a decision support algorithm to improve clinicians' chemotherapy-induced peripheral neuropathy assessment and management practices: a two-phase, longitudinal study.
    Knoerl R; Mazzola E; Hong F; Salehi E; McCleary N; Ligibel J; Reyes K; Berry DL
    BMC Cancer; 2021 Mar; 21(1):236. PubMed ID: 33676431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA.
    Wolf SL; Barton DL; Qin R; Wos EJ; Sloan JA; Liu H; Aaronson NK; Satele DV; Mattar BI; Green NB; Loprinzi CL
    Support Care Cancer; 2012 Mar; 20(3):625-32. PubMed ID: 21479990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring Patients' Understanding of Chemotherapy-Induced Peripheral Neuropathy.
    Knoerl R; Berry DL; Meyerhardt J; Reyes K; Salehi E; Gewandter JS
    J Cancer Educ; 2023 Jun; 38(3):906-912. PubMed ID: 35927535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724).
    Albany C; Dockter T; Wolfe E; Le-Rademacher J; Wagner-Johnston N; Einhorn L; Lafky JM; Smith E; Pachman D; Staff N; Ma C; Loprinzi CL; Costello BA
    Support Care Cancer; 2021 Feb; 29(2):833-840. PubMed ID: 32500206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single-arm trial (MiroCIP study).
    Misawa S; Denda T; Kodama S; Suzuki T; Naito Y; Kogawa T; Takada M; Suichi T; Shiosakai K; Kuwabara S;
    BMC Cancer; 2023 Nov; 23(1):1098. PubMed ID: 37951905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Pain on Symptom Burden in Chemotherapy-Induced Peripheral Neurotoxicity.
    Mahfouz FM; Li T; Timmins HC; Horvath LG; Harrison M; Grimison P; Marx G; Goldstein D; Park SB
    J Natl Compr Canc Netw; 2024 Feb; 22(2):108-116. PubMed ID: 38364373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy.
    Mizrahi D; Park SB; Li T; Timmins HC; Trinh T; Au K; Battaglini E; Wyld D; Henderson RD; Grimison P; Ke H; Geelan-Small P; Marker J; Wall B; Goldstein D
    JAMA Netw Open; 2021 Feb; 4(2):e2036695. PubMed ID: 33587134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practice.
    Nyrop KA; Deal AM; Reeder-Hayes KE; Shachar SS; Reeve BB; Basch E; Choi SK; Lee JT; Wood WA; Anders CK; Carey LA; Dees EC; Jolly TA; Kimmick GG; Karuturi MS; Reinbolt RE; Speca JC; Muss HB
    Cancer; 2019 Sep; 125(17):2945-2954. PubMed ID: 31090930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring Chemotherapy-Induced Peripheral Neuropathy Management Practice Patterns Among Oncology Clinicians.
    Kanzawa-Lee G; Krauss JC; Knoerl R
    Semin Oncol Nurs; 2024 Oct; 40(5):151685. PubMed ID: 38937199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer survivors: a comparison of patient-reported outcomes and quantitative sensory testing.
    Zhi WI; Chen P; Kwon A; Chen C; Harte SE; Piulson L; Li S; Patil S; Mao JJ; Bao T
    Breast Cancer Res Treat; 2019 Dec; 178(3):587-595. PubMed ID: 31456070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the efficacy of an electronic symptom assessment and self-care intervention to preserve physical function in individuals receiving neurotoxic chemotherapy.
    Knoerl R; Weller E; Halpenny B; Berry D
    BMC Cancer; 2018 Dec; 18(1):1203. PubMed ID: 30514351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mapping chemotherapy-induced peripheral neuropathy phenotype and health-related quality of life in patients with cancer through exploratory analysis of multimodal assessment data.
    Wang M; Molassiotis A
    Support Care Cancer; 2022 May; 30(5):4007-4017. PubMed ID: 35059866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Self-Guided Online Cognitive Behavioral Strategies for Chemotherapy-Induced Peripheral Neuropathy: A Multicenter, Pilot, Randomized, Wait-List Controlled Trial.
    Knoerl R; Smith EML; Barton DL; Williams DA; Holden JE; Krauss JC; LaVasseur B
    J Pain; 2018 Apr; 19(4):382-394. PubMed ID: 29229430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing gait, balance, and muscle strength among breast cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): study protocol for a randomized controlled clinical trial.
    Teran-Wodzinski P; Haladay D; Vu T; Ji M; Coury J; Adams A; Schwab L; Visovsky C
    Trials; 2022 Apr; 23(1):363. PubMed ID: 35477489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk.
    Bao T; Basal C; Seluzicki C; Li SQ; Seidman AD; Mao JJ
    Breast Cancer Res Treat; 2016 Sep; 159(2):327-33. PubMed ID: 27510185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.